310 related articles for article (PubMed ID: 30998268)
1. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
2. ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.
Jin YF; Huang YT; Chen PF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3741-3748. PubMed ID: 32329851
[TBL] [Abstract][Full Text] [Related]
3. The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression.
Liu W; Song Y; Zhang C; Gao P; Huang B; Yang J
Biomed Pharmacother; 2018 Aug; 104():94-101. PubMed ID: 29772445
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells.
Wang L; Li X; Ren Y; Geng H; Zhang Q; Cao L; Meng Z; Wu X; Xu M; Xu K
Cancer Sci; 2019 May; 110(5):1609-1620. PubMed ID: 30868675
[TBL] [Abstract][Full Text] [Related]
5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
6. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
7. Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.
Liu YF; Liu QQ; Zhang YH; Qiu JH
Anal Cell Pathol (Amst); 2016; 2016():4131403. PubMed ID: 27995049
[TBL] [Abstract][Full Text] [Related]
8. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways.
Kwak AW; Park JW; Lee SO; Lee JY; Seo JH; Yoon G; Lee MH; Choi JS; Shim JH
Phytomedicine; 2022 Oct; 105():154383. PubMed ID: 35987016
[TBL] [Abstract][Full Text] [Related]
9. The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells.
Bai Z; Wang J; Wang T; Li Y; Zhao X; Wu G; Yang Y; Deng W; Zhang Z
Cell Physiol Biochem; 2017; 44(5):1882-1895. PubMed ID: 29224019
[TBL] [Abstract][Full Text] [Related]
10. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
[TBL] [Abstract][Full Text] [Related]
11. COPB2 gene silencing inhibits colorectal cancer cell proliferation and induces apoptosis via the JNK/c-Jun signaling pathway.
Wang Y; Xie G; Li M; Du J; Wang M
PLoS One; 2020; 15(11):e0240106. PubMed ID: 33211699
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.
Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S
Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148
[TBL] [Abstract][Full Text] [Related]
13. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
[TBL] [Abstract][Full Text] [Related]
14. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Cai J; Su L; Luo W
Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
[TBL] [Abstract][Full Text] [Related]
15. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
16. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer.
Kim JY; Jung EJ; Park HJ; Lee JH; Song EJ; Kwag SJ; Park JH; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC
Clin Breast Cancer; 2018 Aug; 18(4):e713-e719. PubMed ID: 29217453
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
19. MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3.
Yang L; Men WL; Yan KM; Tie J; Nie YZ; Xiao HJ
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4837-4845. PubMed ID: 30070320
[TBL] [Abstract][Full Text] [Related]
20. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
